SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
KMDA

Kamada Ltd (NASDAQ:KMDA)

IL · Delayed Price · Currency is USD
Also listed: KMDA.TAHealthcare · Drug Manufacturers - Specialty & Generic
$7.74-$0.09 (-1.15%)
 
Market cap
$446M
Insider Score
Health Score
Analyst consensus
Listed since
May 31, 2013
Website
Market Cap$446.45M+13.3%
Revenue (ttm)$196.87M+12.6%
Net Income$24.95M+22.0%
EPS$0.43+19.2%
Shares Out57.68M
PE Ratio17.88
Forward PE13.34
Dividend$0.56(7.24%)
Ex-Dividend DateNov 19, 2026
Volume84,304
Open$7.73
Previous Close$7.83
Day's Range$7.72 - $7.99
52-Week Range$6.63 - $9.35
Beta0.13
AnalystsBuy
Price Target$14.00(+80.88%)
Earnings DateMar 10, 2027

About KMDA

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Address
2 Holzman Street, Rehovot, HM, 7670402, IL
Market Cap
446 million
Employees
462
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.65M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From KMDA’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.15%
5 Days
-5.38%
1 Month
+0.13%
6 Months
-1.15%
1 Year
+13.32%

$KMDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in KMDA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by KMDA's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

KMDA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

KMDA Revenue by Segment or Geography

KMDA's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New KMDA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to KMDA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in KMDA

IZRLARK Israel Innovative Technology ETF$592.62K
DISVDimensional - International Small Cap Value ETF$432.80K
DFISDimensional - International Small Cap ETF$325.98K
DFICDimensional - International Core Equity 2 ETF$280.33K
AIMSAcuitas Small Cap Active ETF$184.26K
DFAXDimensional World ex U.S. Core Equity 2 ETF$103.66K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from KMDA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
78

News check: Record 9-month revenue, raised 2026 guidance, surpassed Q3 estimates, projected double-digit 2027 growth, and raised dividend signal strong financial performance.

Recent Insider Activity

Buys
0
Sells
4
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 12
0255075100Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 12Sep 23Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

AIMSAcuitas Small Cap Active ETF0.23%
IZRLARK Israel Innovative Technology ETF0.18%
IBBQInvesco Nasdaq Biotechnology ETF0.03%
BIBProShares Ultra Nasdaq Biotechnology0.02%

Weight is the stock’s share of each fund’s holdings.